These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33767310)

  • 1. Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions.
    Lin E; Lin CH; Lane HY
    Sci Rep; 2021 Mar; 11(1):6922. PubMed ID: 33767310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of functional outcomes of schizophrenia with genetic biomarkers using a bagging ensemble machine learning method with feature selection.
    Lin E; Lin CH; Lane HY
    Sci Rep; 2021 May; 11(1):10179. PubMed ID: 33986383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bagging ensemble machine learning framework to predict overall cognitive function of schizophrenia patients with cognitive domains and tests.
    Lin E; Lin CH; Lane HY
    Asian J Psychiatr; 2022 Mar; 69():103008. PubMed ID: 35051726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of depression with cognitive insight and socio-occupational outcome in patients with schizophrenia.
    Grover S; Sahoo S; Nehra R; Chakrabarti S; Avasthi A
    Int J Soc Psychiatry; 2017 May; 63(3):181-194. PubMed ID: 28162014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abbreviated quality of life scales for schizophrenia: comparison and utility of two brief community functioning measures.
    Fervaha G; Foussias G; Siddiqui I; Agid O; Remington G
    Schizophr Res; 2014 Apr; 154(1-3):89-92. PubMed ID: 24630140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment.
    Hunter R; Barry S
    Eur Psychiatry; 2012 Aug; 27(6):432-6. PubMed ID: 21602034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial.
    Chen L; Phillips G; Johnston J; Kinon BJ; Ascher-Svanum H; Kollack-Walker S; Succop P; Naber D
    BMC Psychiatry; 2011 Dec; 11():203. PubMed ID: 22204569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
    Lipkovich IA; Deberdt W; Csernansky JG; Sabbe B; Keefe RS; Kollack-Walker S
    BMC Psychiatry; 2009 Jul; 9():44. PubMed ID: 19602273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between social and cognitive functions in people with schizophrenia.
    Tominaga T; Tomotake M; Takeda T; Ueoka Y; Tanaka T; Watanabe SY; Kameoka N; Nakataki M; Numata S; Izaki Y; Sumitani S; Kubo H; Kaneda Y; Ohmori T
    Neuropsychiatr Dis Treat; 2018; 14():2215-2224. PubMed ID: 30214211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Antidepressant Treatment Response and Remission Using an Ensemble Machine Learning Framework.
    Lin E; Kuo PH; Liu YL; Yu YW; Yang AC; Tsai SJ
    Pharmaceuticals (Basel); 2020 Oct; 13(10):. PubMed ID: 33065962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Data-driven diagnosis of spinal abnormalities using feature selection and machine learning algorithms.
    Raihan-Al-Masud M; Mondal MRH
    PLoS One; 2020; 15(2):e0228422. PubMed ID: 32027680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms.
    Cruz BF; Resende CB; Carvalhaes CF; Cardoso CS; Teixeira AL; Keefe RS; Rocha FL; Salgado JV
    Braz J Psychiatry; 2016; 38(3):216-21. PubMed ID: 27304257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative importance of symptoms, cognition, and other multilevel variables for psychiatric disease classifications by machine learning.
    Walsh-Messinger J; Jiang H; Lee H; Rothman K; Ahn H; Malaspina D
    Psychiatry Res; 2019 Aug; 278():27-34. PubMed ID: 31132573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and cognitive dysfunction in people with schizophrenia.
    Ueoka Y; Tomotake M; Tanaka T; Kaneda Y; Taniguchi K; Nakataki M; Numata S; Tayoshi S; Yamauchi K; Sumitani S; Ohmori T; Ueno S; Ohmori T
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):53-9. PubMed ID: 20804809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia.
    Woon PS; Chia MY; Chan WY; Sim K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):463-8. PubMed ID: 20109511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Ensemble Approach to Predict Schizophrenia Using Protein Data in the N-methyl-D-Aspartate Receptor (NMDAR) and Tryptophan Catabolic Pathways.
    Lin E; Lin CH; Hung CC; Lane HY
    Front Bioeng Biotechnol; 2020; 8():569. PubMed ID: 32582679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studies.
    Ritsner M; Kurs R; Ratner Y; Gibel A
    Psychiatry Res; 2005 May; 135(1):65-75. PubMed ID: 15890413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community dysfunction in schizophrenia: rate-limiting factors.
    Bozikas VP; Kosmidis MH; Kafantari A; Gamvrula K; Vasiliadou E; Petrikis P; Fokas K; Karavatos A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):463-70. PubMed ID: 16442195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.